Navigation Links
Soligenix to Present at 15th Annual BIO CEO & Investor Conference

PRINCETON, N.J., Feb. 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber , PhD, will give a corporate presentation at the 2013 BIO CEO & Investor Conference on Tuesday, February 12, at 3:00 PM Eastern Standard Time.  The presentation will take place in the Duke of Windsor Room at the Waldorf Astoria Hotel in New York City.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at  A replay of the presentation will be archived after the conference at the same location.

For more information about the 2013 BIO CEO & Investor Conference, please refer to the conference website at

About Soligenix, Inc.

Soligenix is a development stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as developing its novel innate defense regulator (IDR) technology SGX942 for the treatment of oral Mucositis.  

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShieldTM has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIH.

For further information regarding Soligenix, Inc., please visit the Company's website at  

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
2. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
3. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
5. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
7. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
10. Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
11. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... , Oct. 13, 2015  ContraVir Pharmaceuticals, ... "Company"), a biopharmaceutical company focused on the development ... the closing of its previously announced underwritten public ... and warrants to purchase up to 3,000,000 shares ... combined price to the public of $3.00. The ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Sir Grout of Greater Boston donated an expansive, ... of Ronald McDonald House Charities® (RMHC®). This donation was made in an effort to ... Boston since its inception. , “We believe strongly in the Ronald McDonald House Charities, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
(Date:10/13/2015)... ... 13, 2015 , ... Element Blue ™, a leading ... company, RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom ... approach for customers requiring sensor hardware for critical data environments. , RightSensor™, working ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... NavaFit Inc. ... helps individuals find others to train with, participate in local fitness & sporting ... and Google Play. , “As high medical costs drive us to get more serious ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):